AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (962)	11/20/1997 1:54:00 PM
From: D.Right	of 2173

Dear Henry: The Novo Nordisk's drug is a stimulater for insulin secretion, and it main target population is type II patients who do not inject insulin daily. You know AMLN's pramlintide is not targeting this type of patients in their current clinical IIIs. Don't tell me you don't know that. Yes, the two percent reduction of glycosolated hemoglobin is very good number, but I believe the control here is for those patients who don't use any medicine at all. Correct me if I am wrong. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next